Collection of Sequential Samples From Patients With Malignant Myeloid

Status Not yet recruiting

Clinical Trial Summary

The main objective is to study the genomic, transcriptomic, proteomic epigenomic, metabolomic and immune mechanisms of blasts and microenvironment cells associated with IT resistance through the constitution of a collection associating blood or marrow samples from patients with LA, MDS and MPS marrow samples from patients with LA, MDS and MPS at diagnosis, during treatment and at relapse and relapse and clinical annotations.

Clinical Trial Description

It is a collection of blood, marrow and oral epithelial cell samples taken longitudinally and oral epithelial cells taken longitudinally for each patient included, with each patient included, with the corresponding clinical data. An oral epithelial cell sample will be collected at inclusion from 2 swabs, which will allow extraction of DNA from healthy from healthy cells. During blood sampling necessary for care, an additional 40 ml of blood will be collected of 40 ml of blood will be collected in 10 tubes of 4 ml: 4 EDTA tubes, 4 heparinized heparinized tubes and 2 dry tubes. These additional collections will take place at the following times: - At inclusion - 7 days (+/- 2 days) after initiation of treatment - 14 days (+/- 2 days) after initiation of therapy - 21-42 days after initiation of therapy (early response assessment) - In case of complete remission - In case of relapse or progression During bone marrow punctures required for treatment, 6 ml of bone marrow bone marrow will be collected in 2 tubes of 3 ml: 1 EDTA tube and 1 heparinized tube. heparinized tube. These additional collections will take place at the following times following times: - At inclusion - 21-42 days after initiation of treatment (assessment of early response) early response) - In case of complete remission - In case of relapse or progression Patients will be followed for up to 2 years after inclusion. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05602168
Study type	Interventional
Source	Institut Paoli-Calmettes
Contact	Dominique GENRE, MD
Phone	+33491223778
Email	drci.up@ipc.unicancer.fr
Status	Not yet recruiting
Phase	N/A
Start date	January 2023
Completion date	January 2030

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04966156` - Cancer Rehab Program for Allogenic Bone and Marrow Transplant Patients - CaRE-4-alloBMT	N/A
Recruiting	`NCT05942885` - Hypnosis: a Path to Appeasement	N/A
Recruiting	`NCT05715047` - Intervention for Fatigue in HCT Recipients	N/A
Recruiting	`NCT05142033` - Avera Cancer Sequencing and Analytics Protocol (ASAP)
Completed	`NCT06053918` - Research-Action in Hematology From Hospitalization to Home
Recruiting	`NCT05175508` - Aza With or Without ATRA in Newly Diagnosed Unfit AML or Intermediate,High or Very High Risk MDS	Phase 2/Phase 3
Not yet recruiting	`NCT04822974` - TORQUETENOVIRUS IN CAR-T THERAPY: PREDICTION OF THE CRS	N/A
Not yet recruiting	`NCT06279585` - Physical Therapy in Patients Undergoing Allo-HSCT With cGVHD	N/A
Recruiting	`NCT05753501` - Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies	Phase 1
Recruiting	`NCT05481502` - An Exploratory Study to Evaluate Immune Determinants of the Response to Adoptive Cell Therapy (ACT) in Solid and Hematologic Tumors	N/A
Not yet recruiting	`NCT04412135` - The Point of View of Hematological Cancer Patients and Their Loved Ones Regarding Spirituality
Not yet recruiting	`NCT06377059` - Early Detection of Complications During Immunotherapy for Haematological Malignancy	N/A
Completed	`NCT04235153` - CAncer, NUtrition and Taste - Validation of the CANUT-QVA Questionnaire on Eating Habits in Cancer Patients
Recruiting	`NCT05626764` - QUALITOP - Monitoring Multidimensional Aspects of QUAlity of Life After Cancer ImmunoTherapy, an Open Smart Digital Platform for Personalized Prevention and Patient Management
Active, not recruiting	`NCT04035447` - Symptom Management for YA Cancer Survivors	N/A
Terminated	`NCT03955276` - An Open Label Navigational Investigation of Molecular Profile-Related Evidence Determining Individualized Cancer Therapy for Patients With Incurable Hematologic Malignancies (I-PREDICT Heme)
Recruiting	`NCT03091933` - Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion)	Phase 1/Phase 2
Withdrawn	`NCT01792882` - Prospective Collection of Surplus Surgical Tumor Tissues and Pre-surgical Blood Samples
Recruiting	`NCT05493800` - Evaluate the Safety and Efficacy for Oral Mucositis Prevention of MIT-001 in Auto HSCT	Phase 2
Active, not recruiting	`NCT05690230` - Improving Patient Experience: BMBA	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Collection of Sequential Samples From Patients With Malignant Myeloid Hemopathy for the Study of Treatment Resistance

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms